SCHEMBL6163959

SCHEMBL6163959

O=C(c1cc(-c2ccc(F)cc2)nc2ccccc12)N1CCC(O)C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.64
ALDH1A1 P00352 3/20 0.56
TSHR P16473 2/20 0.56
LMNA P02545 1/20 0.56
CYP2C9 P11712 3/20 0.56
TRPV1 Q8NER1 4/20 0.55
POLB P06746 2/20 0.54
HPGD P15428 2/20 0.54
USP2 O75604 1/20 0.54
TP53 P04637 1/20 0.54
HSD17B10 Q99714 1/20 0.54
RAB9A P51151 1/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
GAA P10253 1/20 0.54
MAPK1 P28482 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
TDP1 Q9NUW8 1/20 0.53
MOK Q9UQ07 1/20 0.53
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7229740 1.00 KDM4E (0.64) KDM4EALDH1A1TSHRLMNACYP2C9
SCHEMBL7229129 1.00 KDM4E (0.64) KDM4EALDH1A1TSHRLMNACYP2C9
SCHEMBL6163364 0.84 CYP2C9 (0.74) KDM4EALDH1A1TSHRLMNACYP2C9
SCHEMBL17434243 0.80 SMN1; SMN2 (0.61) KDM4EALDH1A1TSHRLMNACYP2C9
SCHEMBL17434236 0.80 ALOX5AP (0.49) ALDH1A1TSHRLMNACYP2C9TRPV1
SCHEMBL17434244 0.80 SMN1; SMN2 (0.61) KDM4EALDH1A1TSHRLMNACYP2C9
SCHEMBL17434234 0.80 ALOX5AP (0.49) ALDH1A1TSHRLMNACYP2C9TRPV1
SCHEMBL6163206 0.76 KDM4E (0.59) KDM4EALDH1A1TSHRLMNACYP2C9
SCHEMBL6161778 0.76 KDM4E (0.59) KDM4EALDH1A1TSHRLMNACYP2C9
SCHEMBL6161828 0.76 KDM4E (0.59) KDM4EALDH1A1TSHRLMNACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1337523-B1 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORP (US) 2005-10-19 EP claimed
US-20040048867-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2004-03-11 US claimed
EP-1337523-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2003-08-27 EP claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US claimed
US-20020161008-A1 2,4-Substituted pyridine derivatives NEUROGEN CORPORATION 2002-10-31 US claimed
WO-2002014269-A2 2,4-SUBSTITUTED PYRIDINE DERIVATIVES NEUROGEN CORPORATION (US) 2002-02-21 WO claimed
US-6559163-B2 Agonists, antagonists or inverse agonists for GABAA brain receptors; useful in diagnosis and treatment of anxiety, depression NEUROGEN CORPORATION 2003-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161008-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 KDM4E 613/4885ALDH1A1 922/4885TSHR 412/4885
US-20040048867-A1 2,4-Substituted pyridine derivatives GABARAP, GABRB1, GABARAPL1 KDM4E 613/4885ALDH1A1 922/4885TSHR 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.